Financial Performance - The company's operating revenue for 2021 was ¥1,994,333,825.91, representing a year-over-year increase of 25.68% from ¥1,586,860,209.21 in 2020[18]. - Net profit attributable to shareholders for 2021 was ¥673,309,413.17, an increase of 11.17% compared to ¥605,684,140.68 in 2020[18]. - The net profit after deducting non-recurring gains and losses was ¥616,473,100.55, up 11.48% from ¥552,983,388.80 in 2020[18]. - The net cash flow from operating activities reached ¥673,261,691.25, reflecting a 21.14% increase from ¥555,769,602.12 in 2020[18]. - Total assets at the end of 2021 amounted to ¥3,379,858,314.48, a growth of 28.14% from ¥2,637,596,622.12 at the end of 2020[18]. - The net assets attributable to shareholders increased by 19.42% to ¥2,512,476,209.50 from ¥2,103,900,958.01 in 2020[18]. - The basic earnings per share for 2021 was ¥1.68, an increase of 11.26% from ¥1.51 in 2020[18]. - The diluted earnings per share was ¥1.67, reflecting a 10.60% increase from ¥1.51 in 2020[18]. - The company achieved operating revenue of CNY 1,994,333,825.91, a year-on-year increase of 25.68%[52]. - Net profit attributable to shareholders reached CNY 673,309,413.17, up 11.17% year-on-year, with a basic earnings per share of CNY 1.68[52]. Dividend Policy - The company plans to distribute a cash dividend of 5.00 RMB per 10 shares (including tax) to all shareholders based on the total share capital as of the dividend distribution date[5]. - The total cash dividend amount (including other methods) is 202,569,910 yuan, which accounts for 15.66% of the total distributable profit[156]. - The distributable profit at the end of 2021 is 1,293,423,113.23 yuan, following the principle of the lower of the parent company and consolidated financial statements[156]. - The company will prioritize cash dividends, distributing no less than 20% of the distributable profit each year[154]. - The company has established a three-year shareholder return plan, ensuring a stable and continuous dividend policy[154]. - The company’s cash dividend distribution is subject to the condition of having positive retained earnings and ensuring sustainable operations[156]. Research and Development - The company invested CNY 167,067,162.53 in R&D, marking a 30.50% increase from the previous year[57]. - The company holds 462 patents, including 42 invention patents and 343 utility model patents[57]. - The company acquired 46 new medical device registration certificates during the reporting period, enhancing its product line[57]. - The proportion of R&D investment to operating income increased to 8.38% in 2021 from 8.07% in 2020, indicating a focus on innovation[82]. - The company is increasing R&D investments to develop competitive new products and technologies, addressing the long product registration timelines and associated risks[113]. Market Position and Strategy - The global orthopedic medical device market is projected to reach approximately $47.1 billion by 2024, growing at a CAGR of 3.7% from a current size of $36.5 billion[22]. - The orthopedic medical device industry is characterized by rigid demand, with minimal impact from seasonal and economic fluctuations, suggesting stable growth prospects[22]. - The company has successfully bid for its hip and knee joint product systems in the national centralized procurement for orthopedic consumables, marking a significant achievement in the competitive landscape[22]. - The company is committed to enhancing production and operational efficiency to lower production costs and maintain competitive pricing in the face of centralized procurement[22]. - The company plans to expand its product offerings in orthopedic implants and enter new fields such as neurosurgery and minimally invasive surgery[54]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[5]. - The company has stated that it will face major risks in the future and has detailed its risk management strategies in the report[5]. - The company has implemented risk control measures for derivative investments, including market risk and liquidity risk assessments[93]. - The independent directors support the company's foreign exchange hedging activities to mitigate currency fluctuation risks[93]. - The company has a clear risk assessment and management strategy, utilizing both qualitative and quantitative methods to analyze and prioritize identified risks[169]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operations from its controlling shareholders[118]. - The company is focused on maintaining a transparent relationship with shareholders, ensuring equal treatment and rights for all, especially minority shareholders[117]. - The board of directors consists of 7 members, including 3 independent directors, complying with regulatory requirements[119]. - The supervisory board is composed of 3 members, ensuring oversight of financial status and compliance of management actions[120]. - The company has established a performance evaluation and incentive system linking management compensation to operational performance[122]. Social Responsibility - The company actively participates in social responsibility initiatives, including environmental protection and community support, while ensuring the protection of stakeholder interests[169]. - The company has been recognized for its contributions during the COVID-19 pandemic, providing masks and medical personnel to support local areas[193]. - The company has committed to continuing its efforts in precise poverty alleviation, particularly in education, health, and ecological protection[194]. - The company has implemented measures for pollution prevention, including the installation of dust and acid mist treatment equipment, ensuring compliance with emission standards[185]. - The company emphasizes environmental protection and sustainable development, focusing on resource conservation and waste management through technological innovation and refined management practices[192].

Financial Performance - The company's revenue for Q3 2021 was ¥458,306,325.20, representing a 4.86% increase year-over-year, while the year-to-date revenue reached ¥1,304,888,568.38, up 17.57% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2021 was ¥136,318,454.71, a decrease of 16.43% year-over-year, with a year-to-date net profit of ¥453,480,053.36, reflecting a 6.05% increase[5] - Total operating revenue for the third quarter reached ¥1,304,888,568.38, an increase of 17.5% compared to ¥1,109,859,060.01 in the same period last year[25] - Net profit for the quarter was ¥471,584,415.37, representing a growth of 8.5% from ¥434,752,615.60 in the previous year[26] - The company reported a decrease in other comprehensive income, with a net amount of -¥413,999.98 compared to -¥2,837,183.94 in the previous year[26] - The total profit for the quarter was ¥542,575,411.58, an increase from ¥506,696,921.09 year-over-year[26] Assets and Liabilities - The company's total assets as of the end of Q3 2021 amounted to ¥2,986,712,325.54, which is a 13.24% increase from the end of the previous year[6] - The total liabilities rose to ¥650,072,939.52, up from ¥503,657,636.55, indicating a 28.9% increase[23] - The total equity attributable to shareholders reached ¥2,257,976,528.72, compared to ¥2,103,900,958.01, reflecting a growth of 7.4%[23] - The company's non-current assets totaled ¥899,141,167.33, an increase from ¥663,373,776.92, reflecting a growth of approximately 35.5%[20] - The accounts payable increased to ¥262,316,899.37 from ¥179,833,146.20, showing a rise of about 46% year-over-year[20] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥331,365,409.19, showing an 18.68% increase[5] - The company’s cash flow from operating activities showed improvement, contributing positively to the overall financial health[25] - Net cash flow from operating activities was 331,365,409.19, up from 279,201,662.85 in the previous period, representing a growth of about 18.7%[28] - Total cash outflow from operating activities was 1,087,318,626.93, compared to 903,014,379.20 in the previous period, reflecting an increase of approximately 20.5%[28] - The company received 4,577,492,606.00 in cash from investment recoveries, a substantial increase from 2,287,796,000.00 in the previous period, representing a growth of about 100.3%[28] Shareholder Information - The total number of common stock shareholders at the end of the reporting period was 29,669[14] - The largest shareholder, Changdu Dabotong Medical Investment Management Co., Ltd., holds 44.41% of shares, totaling 179,928,000 shares[14] Inventory and Receivables - The company's inventory as of the end of Q3 2021 was ¥704,793,010.08, a 30.03% increase due to the acquisition of subsidiary inventory and new product additions[11] - The accounts receivable increased by 32.38% to ¥385,046,735.86, primarily due to increased sales and customers opting for year-end concentrated payments[11] - Accounts receivable increased to ¥385,046,735.86 from ¥290,865,345.89, reflecting a growth of approximately 32.4% year-over-year[19] - Inventory as of September 30, 2021, was ¥704,793,010.08, up from ¥542,019,638.48, indicating an increase of about 30%[20] Management and Expenses - Management expenses for Q3 2021 were ¥61,820,961.86, reflecting a 41.23% increase due to salary adjustments and personnel increases[11] - Research and development expenses increased to ¥109,059,097.62, a rise of 28.7% compared to ¥84,746,388.56 in the same quarter last year[25] Strategic Initiatives - The company won all bids in the centralized procurement for orthopedic trauma and joint products in July and September 2021, which may impact future sales[16] - The company plans to actively adjust its business strategy in response to the impact of centralized procurement on distributor purchases[16] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[25] Audit and Compliance - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[36] - The report indicates that the company is in compliance with the new leasing standards effective from 2021, although it is not applicable for retrospective adjustments[36]

大博医疗科技股份有限公司 2021 年半年度报告全文 大博医疗科技股份有限公司 2021 年半年度报告 2021 年 08 月 1 大博医疗科技股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人林志雄、主管会计工作负责人柯碧灵及会计机构负责人(会计主 管人员)罗春梅声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺。投 资者及相关人士均应对此保持足够的风险认识，并且应当理解计划、预测与承 诺之间的差异。 公司已在本报告中详细描述未来将面临的主要风险及应对措施，详情请查 阅本报告"第三节 管理层讨论与分析"之"十、公司面临的风险和应对措施" 部分，请投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 大博医疗科技股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 . -- ...

Financial Performance - The company's operating revenue for 2020 was ¥1,586,860,209.21, representing a 26.21% increase compared to ¥1,257,317,998.46 in 2019[20]. - The net profit attributable to shareholders for 2020 was ¥605,684,140.68, a 30.12% increase from ¥465,490,905.65 in 2019[20]. - The net profit after deducting non-recurring gains and losses was ¥552,983,388.80, up 30.78% from ¥422,846,292.59 in 2019[20]. - The basic and diluted earnings per share for 2020 were both ¥1.51, reflecting a 30.17% increase from ¥1.16 in 2019[20]. - The total assets at the end of 2020 were ¥2,637,596,622.12, a 17.81% increase from ¥2,238,773,031.97 at the end of 2019[20]. - The net assets attributable to shareholders at the end of 2020 were ¥2,103,900,958.01, a 22.19% increase from ¥1,721,832,928.59 at the end of 2019[20]. - The company reported a net cash flow from operating activities of ¥555,769,602.12, which is a 28.09% increase from ¥433,877,268.05 in 2019[20]. - The overall gross profit margin for the reporting period was 85.87%[72]. - The company achieved operating revenue of ¥1,586,860,209.21, a year-on-year increase of 26.21%[72]. - Net profit attributable to shareholders reached ¥605,684,140.68, reflecting a growth of 30.12% compared to the previous year[72]. - The company’s cash flow from operating activities was ¥555,769,602.12, up by 28.09% year-on-year[72]. Dividend Policy - The company plans to distribute a cash dividend of 8 RMB per 10 shares to all shareholders, totaling a significant return on investment[3]. - The cash dividend for 2020 was CNY 321,788,640.00, which accounts for 53.13% of the net profit attributable to shareholders[174]. - The cash dividend per 10 shares is CNY 8.00 (including tax), with a total share capital of 402,235,800 shares used for the calculation[176]. - The company prioritizes cash dividends, distributing no less than 20% of the available profits to shareholders annually, provided there are no significant capital expenditure plans[161]. - The company has a three-year shareholder return plan (2020-2022) that ensures cash dividends are not less than 20% of the distributable profits each year[170]. - The company plans to increase stock dividends and capital reserve transfers if net profits continue to grow, while maintaining the 20% cash dividend distribution[170]. - The board of directors will propose dividend plans after each fiscal year, which will be subject to shareholder approval[170]. - Adjustments to the dividend policy require approval from more than half of the board and two-thirds of the voting rights at the shareholder meeting[163]. - The company emphasizes the importance of considering shareholder opinions, especially those of minority shareholders, in its dividend distribution policies[169]. Business Operations - The company has maintained its main business operations without any changes since its listing[18]. - The company’s main business involves the production, research and development, and sales of high-value medical consumables, with no significant changes reported during the period[30]. - The company’s product categories include orthopedic trauma implants, spinal implants, and minimally invasive surgical consumables, among others[30]. - The company reported a comprehensive range of implantable medical devices, including trauma, spinal, neurosurgical, joint, sports medicine, oral implant, and minimally invasive surgical products[39]. - The trauma implant products are primarily used for surgical treatment of pathological and traumatic fractures in adults and children, including intramedullary nails and metal plates[41]. - The spinal implant products are designed for surgical treatment of various spinal disorders caused by trauma, degeneration, or deformity, including pedicle screw systems and interbody fusion devices[41]. - The company’s joint implant products include artificial hip and knee joint systems for treating various forms of arthritis and joint diseases[41]. - The company’s minimally invasive surgical products include disposable laparoscopic puncture devices for establishing access in minimally invasive surgeries[41]. Research and Development - The company invested ¥128,023,696.19 in R&D, which is a 27.54% increase from the previous year[79]. - The company has established a complete R&D system with a team of professionals from various disciplines, focusing on orthopedic implant products[62]. - The number of R&D personnel rose by 18.18% to 416, with R&D personnel accounting for 16.67% of the total workforce[101]. - The company aims to enhance its R&D capabilities by increasing investment in its technology center and expediting the use of the new R&D building to support core business and promote sustainable development[143]. - The company will increase R&D investment to maintain competitiveness in orthopedic consumables, focusing on innovative product development[153]. Market and Competition - The orthopedic implant market in China is experiencing steady growth due to factors such as an aging population and increasing medical demand[59]. - The company aims to strengthen its market position through continuous investment in R&D and production capacity expansion[82]. - The company plans to expand its marketing network by increasing distribution points and enhancing regional competitiveness, targeting a higher market share in secondary and tertiary hospitals[144]. - The company faces risks from market competition and potential product price declines, prompting strategies to optimize product structure and expand production[147]. - Regulatory changes in the healthcare sector may impact the high-value consumables market, necessitating timely adjustments to business strategies[148]. Compliance and Governance - The company has committed to ensuring the authenticity, accuracy, and completeness of its public announcements, taking legal responsibility for any misstatements[188]. - The company has disclosed that there are no undisclosed related party transactions during the reporting period, adhering to regulatory requirements[182]. - The company has pledged to avoid related party transactions and ensure that any unavoidable transactions are conducted on a fair and reasonable basis[182]. - The company will not engage in any activities that could harm the interests of its shareholders or the company itself[182]. - The company has established a mechanism to ensure compliance with its commitments and will take corrective actions if any commitments are not fulfilled[182]. Audit and Financial Reporting - The company has reported a comprehensive financial report ensuring accuracy and completeness, with all board members present for the review[3]. - The company has appointed Tianjian Accounting Firm as its auditor, with the signing accountants being Fang Guohua and Li Mingming[19]. - The company has maintained a continuous relationship with Tianjian Accounting Firm for 8 years, with an audit fee of 800,000 CNY for the current period[194]. - The company has not faced any penalties or corrective actions during the reporting period[199]. - The company has reported no significant accounting errors requiring restatement during the reporting period[191].

大博医疗科技股份有限公司 2021 年第一季度报告全文 大博医疗科技股份有限公司 2021 年第一季度报告 2021 年 04 月 1 大博医疗科技股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人林志雄、主管会计工作负责人柯碧灵及会计机构负责人(会计主 管人员)罗春梅声明：保证季度报告中财务报表的真实、准确、完整。 2 大博医疗科技股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 | --- | --- | --- | --- | --- | --- | |-------|-------|----------------------------------|------------------|------------------|---------------------------| | □ | 是 | √ 否 | 本报告期 | 上年同期 | ...

大博医疗科技股份有限公司 2019 年第三季度报告正文 大博医疗科技股份有限公司 2020 年第三季度报告 2020 年 10 月 1 大博医疗科技股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人林志雄、主管会计工作负责人柯碧灵及会计机构负责人(会计主 管人员)罗春梅声明：保证季度报告中财务报表的真实、准确、完整。 2 大博医疗科技股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------------|--------|-----------------------------------------------------|---------------- ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥672,795,529.06, representing a 23.80% increase compared to ¥543,448,928.40 in the same period last year[22]. - The net profit attributable to shareholders was ¥264,485,188.61, an increase of 27.38% from ¥207,634,426.46 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥230,066,861.66, up 20.19% from ¥191,425,280.92[22]. - The net cash flow from operating activities was ¥159,311,626.30, a significant increase of 74.29% compared to ¥91,407,479.65 in the same period last year[22]. - Basic and diluted earnings per share were both ¥0.6609, reflecting a 27.93% increase from ¥0.5166[22]. - Total assets at the end of the reporting period were ¥2,497,177,085.23, an increase of 11.54% from ¥2,238,773,031.97 at the end of the previous year[22]. - The net assets attributable to shareholders were ¥1,758,687,159.13, up 2.14% from ¥1,721,832,928.59 at the end of the previous year[22]. - The overall gross profit margin for the reporting period was 85.63%[69]. - The gross profit margin for the medical device manufacturing sector was 85.64%, slightly up by 0.99% from the previous year[81]. Business Operations - The main business of the company includes the production, research and development, and sales of high-value medical consumables, with no significant changes reported during the period[29]. - The company’s primary products include orthopedic trauma implants, spinal implants, joint implants, minimally invasive surgical consumables, and dental implants[29]. - The company has established a comprehensive procurement management system to ensure the quality of purchased materials and regulate procurement behavior[40]. - The procurement plan is determined annually based on sales forecasts, with the procurement department responsible for sourcing from qualified suppliers[41]. - Suppliers are required to provide necessary certifications and must pass ISO9001/ISO13485 quality system certification[42]. - The procurement department follows a principle of prioritizing quality over price when selecting suppliers and negotiating contracts[43]. - The company maintains a stable growth in business, driven by product quality comparable to international first-line brands, a comprehensive marketing network, extensive clinical acceptance, continuous innovation and R&D capabilities, and an excellent management team[55]. - The orthopedic implant medical consumables market in China is experiencing annual growth due to factors such as a large population base, accelerated aging, and increasing medical demand[56]. - The company has established a marketing operation center with over 400 sales and support personnel to enhance sales capabilities and marketing functions[51]. - The sales model primarily consists of a distribution model, where products are sold to distributors who then sell to end-users, and a delivery model in specific regions[50]. - The company implements a strict production process in accordance with ISO13485 and other regulatory standards, ensuring product quality through comprehensive monitoring and measurement[48]. - The company has a framework production plan based on annual sales forecasts, adjusting monthly production plans according to inventory and demand[47]. - The company actively engages in market promotion through training, academic support, and participation in medical conferences, enhancing brand awareness and product recognition[54]. Research and Development - Research and development investment amounted to ¥55,442,412.75, a 30.71% increase compared to the previous year, reflecting the company's commitment to product innovation[73]. - The company holds 252 patents, including 30 invention patents, indicating a strong R&D capability[59]. - The company has 39 batches of registration certificates currently under application, covering various medical fields, enhancing its competitive edge[73]. - The company obtained 5 new registration certificates during the reporting period, including key products in trauma and spine categories, strengthening its product lineup[73]. - Significant investment in R&D for orthopedic consumables is necessary, as failure to develop competitive new products could diminish market competitiveness and future profitability[109]. - The company is committed to increasing R&D investment to align with industry trends and ensure sustainable development through product innovation[109]. Risk Management - The company has outlined future risks and corresponding measures in the report, emphasizing the importance of risk awareness for investors[5]. - The company faces risks from market competition and product price declines, prompting strategies to optimize product structure and develop new products[107]. - The company is closely monitoring national regulatory dynamics and policy changes to adjust its operational strategies accordingly[107]. - The company faces risks from foreign operations and exchange rate fluctuations, particularly in countries like Russia, Ukraine, and Chile, which could impact sales and purchasing power due to currency depreciation[108]. - The company plans to accelerate the establishment of a global sales network to mitigate market volatility risks and closely monitor exchange rate fluctuations to reduce foreign exchange losses[108]. Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares[6]. - The company has committed to ensuring the authenticity, accuracy, and completeness of its listing announcement[128]. - The company has pledged to compensate investors for direct losses incurred due to reliance on its commitments, with measures including using its own funds for compensation[122]. - The company confirmed that there were no undisclosed related party transactions during the reporting period[124]. - The company will avoid related party transactions with its subsidiaries and ensure that any unavoidable transactions are conducted on fair and reasonable terms[124]. - The company has committed to not using its position to seek improper benefits that could harm the interests of its shareholders[124]. - The company has established a mechanism to ensure compliance with its commitments, including restrictions on salary increases for executives until all commitments are fulfilled[122]. - The company has committed to not engaging in any activities that could harm the interests of its shareholders or the company itself[124]. - The company will not issue any securities until it has fully addressed any negative impacts from unfulfilled commitments[122]. - The company reported a commitment to stabilize its stock price for three years post-IPO, with measures including share buybacks if the stock price remains below net asset value per share[120]. - The company and its actual controllers committed to ensuring that the prospectus does not contain false records or misleading statements, bearing legal responsibility for its accuracy[120]. - The actual controllers have made commitments to avoid competition with the company and its subsidiaries[128]. Environmental and Social Responsibility - The company has implemented measures for pollution prevention, including the installation of dust and acid mist treatment equipment, ensuring compliance with emission standards[158]. - The company conducted internal monitoring of wastewater discharge twice a month and commissioned external testing at least once a year[162]. - The company completed the environmental impact assessment for its expansion project in June 2020, receiving approval from the ecological environment bureau[163]. - The company made a targeted donation of 300,000 CNY for poverty alleviation in June 2020[160]. - The company plans to actively respond to national poverty alleviation initiatives, enhancing collaboration with relevant organizations[165]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 11,882, with the largest shareholder, Changdu Dabotong Medical Investment Management Co., Ltd., holding 44.73% of shares, equating to 179,928,000 shares[180]. - Dabotong Medical International Investment Co., Ltd. held 22.89% of shares, amounting to 92,064,290 shares, while Lin Zhijun held 20.09% with 80,807,710 shares[186]. - The top ten shareholders did not engage in any repurchase agreements during the reporting period[191]. - There were no changes in the controlling shareholder or actual controller during the reporting period[192]. - The company does not have any preferred shares or convertible bonds as of the reporting period[195][198].

Dividend and Financial Performance - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares (including tax) to all shareholders based on the total share capital as of the equity distribution date[4]. - The company's operating revenue for 2019 was ¥1,257,317,998.46, representing a 62.77% increase compared to ¥772,469,529.01 in 2018[24]. - The net profit attributable to shareholders for 2019 was ¥465,490,905.65, a 25.32% increase from ¥371,453,093.03 in 2018[24]. - The net profit excluding non-recurring gains and losses was ¥422,846,292.59, up 30.23% from ¥324,695,816.45 in 2018[24]. - The company's cash flow from operating activities for 2019 was ¥433,877,268.05, a 29.56% increase from ¥334,876,268.42 in 2018[24]. - Basic and diluted earnings per share for 2019 were both ¥1.16, reflecting a 24.73% increase from ¥0.93 in 2018[26]. - The total assets at the end of 2019 were ¥2,238,773,031.97, a 34.46% increase from ¥1,665,064,091.68 at the end of 2018[26]. - The net assets attributable to shareholders at the end of 2019 were ¥1,721,832,928.59, up 19.58% from ¥1,439,889,332.18 at the end of 2018[26]. - The company reported quarterly revenues of ¥387,107,300.13 in Q4 2019, with a total annual revenue of ¥1,257,317,998.46[29]. - The company's gross profit margin stood at 85.61% during the reporting period[82]. Business Operations and Strategy - The company has not reported any changes in its main business since its listing[21]. - The company’s main business involves the production, research, and sales of high-value medical consumables, with no significant changes reported in 2019[36]. - The company has a diverse product range including orthopedic trauma implants, spinal implants, and minimally invasive surgical consumables[36]. - The company reported a focus on spinal fusion devices, cranioplasty titanium mesh series, and other neurosurgical implant consumables for various surgical treatments[44]. - The company’s product offerings include hip and knee joint prostheses for conditions such as osteoarthritis and rheumatoid arthritis, indicating a broad market presence in orthopedic solutions[47]. - The company employs a distribution-focused sales model, primarily through dealers, with a significant increase in sales revenue and expenses in regions implementing a two-invoice system[60]. - The company has established a marketing operation center with over 400 sales and support personnel, covering all regions in mainland China and some overseas areas[61]. - The company has expanded its consolidation scope to include additional subsidiaries, enhancing its operational footprint[103]. Research and Development - The company has developed a comprehensive R&D system with 227 patents, including 30 invention patents, and holds 69 Class III medical device registrations[71]. - R&D investment amounted to ¥100,377,356.04, reflecting a growth of 54.88% year-on-year[85]. - The company is actively pursuing new product development in the orthopedic sector, with several products expected to launch in the coming years[116]. - The company plans to enhance its R&D capabilities and accelerate new product development, particularly in orthopedic implants and minimally invasive surgery[196]. - The company will invest in a new R&D technology center to improve its independent R&D capabilities and product development efficiency[199]. Quality Control and Compliance - The procurement management system is designed to ensure quality and compliance, with suppliers required to meet ISO9001/ISO13485 certification standards[49]. - The company emphasizes strict adherence to ISO13485 and other regulatory standards in its production processes to ensure product quality and compliance[58]. - The company emphasizes product quality, adhering to international standards and maintaining strict quality management throughout the production process[73]. - The company is committed to maintaining high standards of quality and compliance in its product development processes, ensuring safety and efficacy for patients[114]. Market Trends and Opportunities - The orthopedic implant market in China is growing due to an aging population and increasing medical demand, presenting opportunities for domestic brands[67]. - The company is strategically positioning itself for future growth by diversifying its product offerings and enhancing its technological capabilities[114]. - The company is leveraging its expertise in orthopedic solutions to capture a larger share of the growing global medical device market[114]. Subsidiary Performance - Subsidiary Shiai De (Xiamen) Medical Equipment Co., Ltd. reported a total asset growth of 93.76% and a net asset growth of 63.45% year-on-year as of December 31, 2019[191]. - Subsidiary Sako (Xiamen) Medical Technology Co., Ltd. experienced total asset growth of 37.45% and net asset growth of 62.17% year-on-year as of December 31, 2019[191]. - Subsidiary Boyi Ning (Xiamen) Medical Devices Co., Ltd. achieved total asset growth of 98.60% and net asset growth of 18.86% year-on-year as of December 31, 2019[194]. Cash Flow and Investments - Operating cash inflow for 2019 was CNY 1,395.27 million, an increase of 48.85% compared to 2018, primarily due to expanded sales leading to increased collections[124]. - Investment cash inflow reached CNY 4,133.49 million, a 35.33% increase from the previous year, driven by increased frequency and scale of bank financial product purchases[125]. - The total amount of raised funds in 2017 was RMB 42,621.86 million, with RMB 21,471.65 million utilized by the end of the reporting period, representing 50.38% of the total raised[141].

Financial Performance - The company's operating revenue for Q1 2020 was ¥230,304,243.38, representing a 5.89% increase compared to ¥217,501,203.83 in the same period last year[8]. - The net profit attributable to shareholders was ¥89,190,527.51, up 7.85% from ¥82,700,447.72 year-on-year[8]. - The net profit after deducting non-recurring gains and losses decreased by 6.62% to ¥68,943,151.81 from ¥73,832,663.91 in the previous year[8]. - The basic earnings per share for the period was ¥0.22, a 4.76% increase from ¥0.21 in the same period last year[8]. - The weighted average return on net assets was 5.05%, down from 5.58% in the previous year[8]. - Total operating revenue for the current period reached ¥230,304,243.38, an increase from ¥217,501,203.83 in the previous period, representing a growth of approximately 5.8%[38]. - Net profit for the current period was ¥89,492,535.97, compared to ¥85,915,896.51 in the previous period, reflecting an increase of approximately 3.0%[40]. - The total profit for the current period was ¥106,055,139.17, compared to ¥104,193,814.96 in the previous period, indicating a growth of about 1.8%[40]. - Comprehensive income for the current period totaled ¥86,697,207.88, slightly up from ¥85,954,070.48 in the previous period[41]. Cash Flow - The net cash flow from operating activities was negative at -¥8,235,865.28, a decline of 125.16% compared to ¥32,733,896.57 in the same period last year[8]. - Cash received from other operating activities increased by 168.27% to ¥25,209,568.12 from ¥9,397,078.38, primarily due to higher government subsidies[19]. - Cash paid for operating activities increased by 206.11% to ¥82,127,296.13 from ¥26,829,182.48, largely due to increased market promotion expenses[19]. - Operating cash inflow totaled CNY 266,198,063.15, an increase of 24.4% from CNY 213,900,427.60 in the previous period[48]. - The company reported a net increase in cash and cash equivalents of CNY 16,716,522.10, compared to a decrease of CNY -33,583,085.67 in the previous period[49]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,266,235,337.12, an increase of 1.23% from ¥2,238,773,031.97 at the end of the previous year[8]. - The total liabilities decreased to CNY 421,013,802.70 from CNY 485,310,074.39, a reduction of about 13.2%[32]. - The company's equity attributable to shareholders increased to CNY 1,812,928,947.69 from CNY 1,721,832,928.59, showing a growth of approximately 5.3%[33]. - The company reported a decrease in current liabilities to CNY 363,684,950.82 from CNY 425,753,582.13, a decline of approximately 14.6%[32]. - Total assets amounted to CNY 2,238,773,031.97, with non-current assets totaling CNY 591,066,638.88[55]. Expenses - Total operating costs amounted to ¥146,747,056.04, up from ¥114,607,844.51, indicating a rise of about 28.0%[39]. - Research and development expenses increased by 35.20% to ¥24,639,137.42 from ¥18,223,591.57, reflecting higher personnel costs and increased investment in new product development[18]. - Sales expenses rose by 57.84% to ¥86,875,731.80 from ¥55,039,458.93, driven by increased market development and technical service costs[18]. - The company reported a decrease in tax expenses to ¥16,562,603.20 from ¥18,277,918.45, a reduction of approximately 9.4%[40]. Government Subsidies - The company received government subsidies amounting to ¥23,806,269.18 during the reporting period[9]. - Other income surged by 652.16% to ¥23,806,269.18 from ¥3,165,074.42, mainly due to increased government subsidies received during the period[18].

大博医疗科技股份有限公司 2019 年第三季度报告全文 大博医疗科技股份有限公司 2019 年第三季度报告 2019 年 10 月 1 大博医疗科技股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人林志雄、主管会计工作负责人林志雄及会计机构负责人(会计主 管人员)罗春梅声明：保证季度报告中财务报表的真实、准确、完整。 2 大博医疗科技股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------|-----------------------------------------------------|----------------|-------------------------- ...